HRB Open Research

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

This first pragmatic randomised pilot trial of four once-weekly adjunctive ketamine infusions in hospitalised patients with major depression found the infusions were generally safe and well tolerated but produced no significant difference in HRSD-24 scores versus midazolam. The study indicates a definitive trial of adjunctive ketamine is feasible.

Published

January 27, 2022

Journal

HRB Open Research

Authors

Foley, M., Gallagher, B., Gusciute, G., McLoughlin, D. M., Shanahan, E., Slattery, C. M.